Efficacy News and Research

RSS

Molecular Keyhole Discovery Unlocks New Target for Pain Therapies

Researchers at VIB, VUB, and KU Leuven have identified a tiny binding site, a molecular 'keyhole', in the TRPM3 ion channel, a crucial sensor in pain signaling.

22 Apr 2026

New Data Demonstrates the Unique Scalability of Evaxion’s AI-Immunology™ Platform in Glioblastoma

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform’s ability to also potentially develop vaccines for glioblastoma (brain cancer).

From Evaxion A/S 21 Apr 2026

How Mitochondrial Damage Accelerates Stem Cell Aging

Hematopoietic stem cells (HSCs), the cells that produce all blood cell types, start to lose their efficacy as one ages, which eventually reduces the ability to maintain healthy blood and a robust immune system.

17 Apr 2026

Researchers Develop 3D Organoids that Reflect the Complexity of Brain Tumors

Efforts to identify and evaluate next-generation therapeutics for pediatric brain tumors are easily stymied by the quality and availability of laboratory models for research. To address this issue, scientists at St. Jude Children's Research Hospital developed patient-derived tumor organoids and tumor organoid xenografts that accurately reflect the biologic underpinnings of embryonal brain tumors.

16 Apr 2026

Semen-Derived Exosomes Eye Drops to Treat Retinoblastoma

Innovative eye drops using semen-derived exosomes target retinoblastoma, improving therapeutic delivery and preserving ocular function in preclinical models.

8 Apr 2026

Tumors Disable Dendritic Cells by Decreasing Mitochondrial Fitness

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer - and how restoring their energy production can improve immunotherapy.

3 Apr 2026

How To Create Long-Lasting Immune Cells For Stronger Vaccines

Scientists at the University of Wisconsin School of Veterinary Medicine have identified a potential approach to develop longer-lasting vaccines for respiratory viruses such as influenza and the coronavirus that causes COVID-19.

1 Apr 2026

Novel Immunotherapy Disrupts the Protective Tumor Microenvironment Ecosystem

Chimeric antigen receptor T-cell therapy - CAR T for short - has been a major advance in treating blood cancers like leukemia and lymphoma. But the immunotherapy has struggled against solid tumors for two main reasons: tumor cells often don't share one consistent surface target, and many solid tumors are protected by a dense network of scar tissue and immune-suppressive cells that blocks T cells.

31 Mar 2026

Novel Phage W5 Offers a Sustainable Solution for Foodborne Salmonella

Researchers from China have identified a novel bacteriophage that offers a highly promising "green" biocontrol solution against foodborne Salmonella.

27 Mar 2026

New Mechanism Links Mitochondria Dysfunction to T Cell Exhaustion

The immune system's killer T cells do a commendable job of detecting and destroying cancer cells. But the harsh environment at the heart of tumors often saps them of their vitality, pushing them into a state of permanent lassitude called "terminal exhaustion."

23 Mar 2026

Engineered Bacteria Deliver Targeted Anticancer Therapy in Tumors

Every year, millions of people are diagnosed with cancer globally; however, current treatments are limited by disease complexity.

18 Mar 2026

EV Engineering Boosts Drug Delivery and Improves Sepsis Survival

The engineered scaffold protein EN144 significantly improves extracellular vesicle therapies, showing potential in sepsis treatment and targeted drug delivery.

18 Mar 2026

Revive Penicillin’s Power by Exploiting Bacteria’s Hidden Weakness

When many disease-causing bacteria come into contact with penicillin, they do not necessarily die immediately, but instead enter a brief survival mode known as antibiotic tolerance.

13 Mar 2026

Genetically Engineered Stem Cells Successfully Overcome Immune Rejection in Mice

A study published today in Stem Cell Reports demonstrates that genetically engineered human pluripotent stem cells (hPSCs) can overcome immune rejection in mice with humanized immune systems, surviving for five months in a stringent transplantation model.

6 Mar 2026